. APOE {epsilon}4 and bapineuzumab: Infusing pharmacogenomics into Alzheimer disease therapeutics. Neurology. 2009 Dec 15;73(24):2052-3. PubMed.


Please login to recommend the paper.


  1. This may be a naive question, but if amyloid deposition in the brain is a critical factor in AD-related behavioral sequelae, why is it so difficult to induce a behavioral modification of statistical relevance following Aβ vaccination, since reports show a strong amyloid plaque clearance effect?

    View all comments by Elliott Mufson

Make a Comment

To make a comment you must login or register.

This paper appears in the following:


  1. Paper Alert-cum-SfN: Bapineuzumab Published, More AN1792 Presented